Janus Henderson Global Life Sciences Fund Class S (JFNSX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.83: the stock has moved about 17% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerJanus Henderson Global Life Sciences Fund Class S (JFNSX) trades at $81.12. Janus Henderson Global Life Sciences Fund Class S (JFNSX) aims for long-term capital growth by investing in life science-oriented companies. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for JFNSX: JFNSX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Janus Henderson Global Life Sciences Fund Class S (JFNSX) Financial Services Profile
Janus Henderson Global Life Sciences Fund Class S (JFNSX) is a financial services fund focused on long-term capital appreciation through investments in companies with a life science orientation. The fund strategically allocates a significant portion of its assets to the life sciences sector, operating within the broader global asset management landscape.
What Is the Investment Thesis for JFNSX?
Janus Henderson Global Life Sciences Fund Class S presents an investment opportunity centered on long-term capital appreciation through targeted exposure to the life sciences sector. With a beta of 0.83, the fund exhibits lower volatility compared to the broader market, potentially offering a more stable investment option. A key value driver is the fund's strategic allocation of at least 25% of its assets to life science companies, positioning it to benefit from industry growth. Ongoing catalysts include continued innovation in biotechnology and pharmaceuticals, driving demand for life science products and services. Potential risks include regulatory changes and market volatility impacting the life sciences sector. The fund's success hinges on the portfolio managers' ability to identify and capitalize on promising opportunities within the life sciences landscape.
Based on FMP financials and quantitative analysis
JFNSX Key Highlights
Market capitalization of $5.54 billion indicates a substantial asset base.
- Beta of 0.83 suggests lower volatility compared to the overall market.
- Strategic allocation of at least 25% of total assets to companies in the life sciences sector.
- Managed by Janus Henderson Investors, a global asset management group with extensive experience.
- Investment objective focused on long-term capital growth.
Who Are JFNSX's Competitors?
JFNSX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CTCAX Columbia Global Technology Growth Fund | $138.28 | +1.13% | $6.27B | — |
| CTHRX Columbia Global Technology Growth Fund Institutional 2 Class | $151.31 | +1.14% | $6.38B | — |
| JAGLX Janus Henderson Global Life Sciences Fund | $85.96 | +0.62% | $5.74B | — |
| JAWWX Janus Henderson Global Research Fund - T Shares | $135.57 | +0.89% | $4.81B | — |
| JDWAX Janus Henderson Global Research Fund Class A | $136.88 | +0.66% | $4.77B | — |
| APO Apollo Global Management, Inc. | $115.35 | +1.17% | $66.4B | 55 5-pillar |
| ALTI AlTi Global, Inc. | $2.88 | -1.20% | $427M | — |
| GROW U.S. Global Investors, Inc. | $2.94 | +2.80% | $37.3M | 57 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JFNSX's Key Strengths?
Focus on a high-growth sector (life sciences).
- Experienced management team at Janus Henderson Investors.
- Clearly defined investment strategy.
- Significant asset base ($5.54B market cap).
What Are JFNSX's Weaknesses?
Sector-specific focus may limit diversification.
- Performance is highly dependent on the life sciences sector.
- No dividend yield may deter some investors.
- Susceptible to regulatory changes affecting the life sciences industry.
What Are the Key Risks for JFNSX?
Regulatory changes impacting the life sciences sector.
- Market volatility affecting investment returns.
- Economic downturn impacting the healthcare industry.
- Competition from other asset management firms.
- Dependence on the performance of the life sciences sector.
What Are JFNSX's Competitive Advantages?
- Expertise of Janus Henderson Investors in the financial services sector.
- Strategic focus on the life sciences sector.
- Established investment process and research capabilities.
- Diversified portfolio of life science companies.
What Does JFNSX Do?
Janus Henderson Global Life Sciences Fund Class S is designed to provide investors with long-term capital growth through strategic investments in the life sciences sector. The fund operates under the principle of investing at least 80% of its net assets in securities of companies believed to have a life science focus. A key aspect of its investment strategy is the commitment to allocate a minimum of 25% of its total assets to companies categorized within the life sciences sector. This concentration allows the fund to capitalize on the growth potential within this specialized area. The fund's investment decisions are guided by portfolio managers who assess companies based on their perceived life science orientation. This involves analyzing various factors, including the company's products, services, research and development activities, and overall involvement in the life sciences industry. By focusing on companies with a strong presence in this sector, the fund aims to benefit from advancements and innovations in areas such as biotechnology, pharmaceuticals, medical devices, and healthcare services. The fund is managed by Janus Henderson Investors, a global asset management group known for its diverse investment strategies and research capabilities. Janus Henderson's expertise in the financial services sector contributes to the fund's ability to navigate the complexities of the life sciences market and identify promising investment opportunities. The fund is based in Denver, USA.
What Products and Services Does JFNSX Offer?
- Invests primarily in securities of companies with a life science orientation.
- Aims for long-term capital growth.
- Allocates at least 80% of net assets to life science companies.
- Invests at least 25% of total assets in companies categorized in the 'life sciences' sector.
- Focuses on companies involved in biotechnology, pharmaceuticals, medical devices, and healthcare services.
- Managed by Janus Henderson Investors.
How Does JFNSX Make Money?
- Generates revenue through management fees charged on assets under management (AUM).
- Investment decisions are guided by portfolio managers who assess companies based on their life science orientation.
- The fund's performance is directly linked to the performance of its investments in life science companies.
What Industry Does JFNSX Operate In?
Janus Henderson Global Life Sciences Fund Class S operates within the global asset management industry, specifically targeting the life sciences sector. The asset management industry is characterized by intense competition, with numerous firms offering a wide range of investment products and services. The fund differentiates itself by focusing on life sciences, a sector driven by innovation, aging populations, and increasing healthcare spending. The competitive landscape includes other specialized funds and general asset managers with exposure to the healthcare and biotechnology industries. The fund's success depends on its ability to identify and capitalize on growth opportunities within the rapidly evolving life sciences market.
Who Are JFNSX's Key Customers?
- Individual investors seeking long-term capital growth.
- Institutional investors looking for exposure to the life sciences sector.
- Retirement savers seeking to diversify their portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a fund, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 42 snapshots
| 2026-08-23 | 47 |
| 2026-08-31 | 47 |
| 2026-09-08 | 47 |
| 2026-09-16 | 47 |
| 2026-09-24 | 47 |
| 2026-10-04 | 47 |
| 2026-10-05 | 47 |
What changed?
The score has stayed at 47.
Over the same 30 days the stock moved -5.9%.
JFNSX Financials
Bull Case vs Bear Case
Bull Case
- Focus on a high-growth sector (life sciences).
- Experienced management team at Janus Henderson Investors.
- Clearly defined investment strategy.
- Significant asset base ($5.54B market cap).
Bear Case
- Sector-specific focus may limit diversification.
- Performance is highly dependent on the life sciences sector.
- No dividend yield may deter some investors.
- Susceptible to regulatory changes affecting the life sciences industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
JFNSX Latest News
No recent news available for JFNSX.
JFNSX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for JFNSX.
Price Targets
Wall Street price target analysis for JFNSX.
JFNSX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for JFNSX; grades run from A+ (80-100) to F (below 30).
Janus Henderson Global Life Sciences Fund Class S Financials Stock: Key Questions Answered
What are the main risks for JFNSX?
As a sector-specific fund, Janus Henderson Global Life Sciences Fund Class S faces risks inherent to the life sciences industry.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.